SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present four abstracts at the 2025 American Society for Radiation Oncology Annual Meeting (ASTRO).
The presentations collectively showcase Artera’s vision to advance the frontier of personalized cancer care, including the first validation of the ArteraAI Prostate Test in an Asian patient cohort; the rapid development and validation of its MMAI biomarker for head and neck cancer; and emerging data demonstrating how MMAI biomarkers offer distinct yet complementary insights to genomic classifiers. Details of the abstracts are below.
Key Presentations at ASTRO 2025
Validation of a prognostic multimodal artificial intelligence (MMAI) model in Asian prostate cancer (PCa) patients (pts) from Singapore (Abstract 1117)
Presented in collaboration with the National Cancer Centre Singapore, this study marks the first validation of the ArteraAI Prostate Test in an Asian prostate cancer population. The test was shown to be an independent prognostic tool in Asian men with prostate cancer, confirming its consistent, bias-free performance across diverse populations and clinical settings.
This validation builds on data presented at the 2024 ASCO Annual Meeting, which demonstrated predictive performance in African American men, another historically underrepresented group in biomarker research.
Development and Validation of a Digital Pathology-Based, Multimodal Artificial Intelligence (MMAI) Biomarker in Patients with Head and Neck Cancer Treated with Definitive Radiation Therapy (Abstract 177)
In the first evidence of its kind, Artera developed and validated a new MMAI biomarker for head and neck cancer in just five months, a testament to the speed and rigor of the Artera platform to address multiple diseases across the therapeutic area. This work was performed in collaboration with NRG Oncology.
The biomarker was prognostic for survival and disease progression, regardless of stage or HPV status, and validated in patients treated with either definitive radiation or surgery. Head and neck cancer is the seventh most common cancer globally, with more than 1.1 million new cases annually, yet there are currently no commercial risk classifiers available. Artera’s MMAI biomarker fills this critical unmet need.
“The breadth of data we’re presenting at ASTRO 2025 highlights the scalability and global potential of Artera’s platform,” said Andre Esteva, CEO and Co-founder of Artera. “We’ve now demonstrated the ability to extend our core technology across new cancer types and patient demographics — rapidly, and with clinical rigor. These moments reinforce our position as a category-defining precision medicine company, and reflect our strategy to build a scalable platform with broad clinical and commercial utility.”
In addition to these studies, Artera will present two more abstracts that further validate the distinct and complementary insights Artera’s MMAI biomarkers can provide alongside existing genomic classifiers, supporting more nuanced, data-driven treatment decisions. These include:
Oral Presentation: Genomic classifier and multimodal AI biomarker in localized prostate cancer: Two sides of the same coin
Abstract Number: Abstract 360
Session Type: Oral Session – Biomarker Breakthroughs in Prostate Cancer
Date and Time: October 1, 11:00 AM PT; Room 154
Poster Presentation: Evaluating the Correlation Between Genomic Classifier and Digital Pathology-Based Multi-Modal AI Biomarkers in Localized Prostate Cancer
Abstract Number: Abstract 3121
Session Type: Poster Session – Radiation and Cancer Biology, Health Care Access and Engagement
Date and Time: September 29, 5:00 PM PT; Hall F, Screen 3
About Artera
Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera’s MMAI platform leverages a patient’s digitized biopsy images along with the patient’s clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials, across different cancers, and is available in multiple versions across the globe.
Artera’s flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions.
Additional MMAI-powered products include the ArteraAI Breast Test (UKCA), the ArteraAI Prostate Biopsy Assay (UKCA), and ArteraAI Prostate (FDA). Artera has regulatory authorization for its medical device product in the US and UK.
Artera’s headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit artera.ai.
Contacts
Media:
Vanessa Donohue
Antenna
[email protected]
